Drug intelligence / Profile preview

Endocal-Max

Development stage
Unknown
Lead developer
Precia Pharma
Modality
Small Molecules
Administration
Oral
01

Overview

Endocal-Max is a comprehensive nutritional supplement developed and marketed by Precia Pharma, primarily indicated for the management of bone-related conditions such as osteoporosis, osteopenia, and calcium deficiency. The formulation is an advanced version of the company's calcium line, combining **calcium orotate** with synergistic vitamins and minerals. Calcium orotate is a highly bioavailable calcium salt of orotic acid that facilitates the transport of calcium across cell membranes directly into tissues like bone and cartilage. To optimize calcium utilization, Endocal-Max includes **cholecalciferol (Vitamin D3)**, which promotes intestinal calcium absorption, and **menaquinone-7 (Vitamin K2-7)**, which activates vitamin K-dependent proteins like osteocalcin to ensure calcium is deposited in the bone matrix rather than the vasculature. The product also contains **methylcobalamin** for nerve health and essential minerals including **zinc**, **magnesium**, and **boron**, which serve as structural components and enzymatic cofactors in bone metabolism.

Brand names
Endocal-Max
Other names
calcium orotate + cholecalciferol + menaquinone-7 + methylcobalamin + zinc + magnesium + boron
02

Targets

GGCX (Gamma-glutamyl carboxylase)VDR (Vitamin D receptor)MTR (Methionine synthase)

Beyond the preview

Go deeper on Endocal-Max.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Endocal-Max.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call